Literature DB >> 31203574

ILC3 cells promote the proliferation and invasion of pancreatic cancer cells through IL-22/AKT signaling.

X Xuan1,2, J Zhou3, Z Tian3, Y Lin4, J Song5, Z Ruan6, B Ni7, H Zhao8, W Yang9.   

Abstract

PURPOSE: Type 3 innate lymphocytes (ILC3s) are reported to be involved in lung cancer, possibly by producing interleukin-22 (IL-22). However, whether ILC3s and their secreted IL-22 molecules contribute to the pathogenesis of pancreatic cancer (PC) remains unclear. To this end, in this study, we investigated the effects and possible mechanisms of ILC3s on PC pathogenesis.
METHOD: The IL-22 and IL-2i2R levels and the ILC3s' frequency in cancer tissues from PC patients and in peripheral blood from PC patients and healthy controls were analyzed by flow cytometry, immunochemistry, or immunofluorescence. The effects of IL-22-induced AKT signaling on the proliferation, invasion, and migration of PC cells were examined by co-culturing PC cell lines with ILC3s isolated from PC tissues, with or without the addition of neutralizing IL-22 antibody, IL-22R antibody or AKT inhibitor.
RESULTS: Our results showed that IL-22 and ILC3s were significantly upregulated in the PBMCs and cancer tissues of PC patients, and the IL-22R level was increased in PC cells. The increased frequency of ILC3s was positively correlated with the clinical features of PC patients. Co-culture experiments indicated that ILC3s promoted the proliferation, invasion, and migration of PC cell lines by secreting IL-22 to activate AKT signaling because IL-22/IL-22R or AKT blockage markedly counteracted such effects on PC cells.
CONCLUSION: Our data demonstrated that ILC3s may promote PC pathogenesis through IL-22/IL-22R-AKT signaling, suggesting a potential intervention target for PC treatment in the future.

Entities:  

Keywords:  AKT signaling; IL-22; IL-22R; ILC3; Pancreatic cancer

Mesh:

Substances:

Year:  2019        PMID: 31203574     DOI: 10.1007/s12094-019-02160-5

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  33 in total

Review 1.  Development and evolution of RORγt+ cells in a microbe's world.

Authors:  Gérard Eberl
Journal:  Immunol Rev       Date:  2012-01       Impact factor: 12.988

2.  Activation of Type 3 innate lymphoid cells and interleukin 22 secretion in the lungs during Streptococcus pneumoniae infection.

Authors:  Laurye Van Maele; Christophe Carnoy; Delphine Cayet; Stoyan Ivanov; Rémi Porte; Emeric Deruy; José A Chabalgoity; Jean-Christophe Renauld; Gérard Eberl; Arndt G Benecke; François Trottein; Christelle Faveeuw; Jean-Claude Sirard
Journal:  J Infect Dis       Date:  2014-02-26       Impact factor: 5.226

Review 3.  Diverse effects of interleukin-22 on pancreatic diseases.

Authors:  Xiuyun Xuan; Zhiqiang Tian; Mengjie Zhang; Jian Zhou; Weiwu Gao; Yi Zhang; Yue Zhang; Bo Lei; Bing Ni; Yuzhang Wu; Weiping Fan
Journal:  Pancreatology       Date:  2018-02-25       Impact factor: 3.996

4.  Metformin decreases IL-22 secretion to suppress tumor growth in an orthotopic mouse model of hepatocellular carcinoma.

Authors:  Dong Zhao; Xi-Dai Long; Tian-Fei Lu; Tao Wang; Wei-Wei Zhang; Yi-Xiao Liu; Xiao-Lan Cui; Hui-Juan Dai; Feng Xue; Qiang Xia
Journal:  Int J Cancer       Date:  2014-11-21       Impact factor: 7.396

5.  Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity.

Authors:  Daniel R Neill; See Heng Wong; Agustin Bellosi; Robin J Flynn; Maria Daly; Theresa K A Langford; Christine Bucks; Colleen M Kane; Padraic G Fallon; Richard Pannell; Helen E Jolin; Andrew N J McKenzie
Journal:  Nature       Date:  2010-03-03       Impact factor: 49.962

6.  Intra-tumoral IFN-γ-producing Th22 cells correlate with TNM staging and the worst outcomes in pancreatic cancer.

Authors:  Elena Niccolai; Antonio Taddei; Federica Ricci; Simona Rolla; Mario Milco D'Elios; Marisa Benagiano; Paolo Bechi; Lapo Bencini; Maria Novella Ringressi; Alessandro Pini; Francesca Castiglione; Daniele Giordano; Maria Antonietta Satolli; Andrea Coratti; Fabio Cianchi; Daniele Bani; Domenico Prisco; Francesco Novelli; Amedeo Amedei
Journal:  Clin Sci (Lond)       Date:  2015-11-20       Impact factor: 6.124

7.  IL-22 is produced by innate lymphoid cells and limits inflammation in allergic airway disease.

Authors:  Christian Taube; Christine Tertilt; Gabor Gyülveszi; Nina Dehzad; Katharina Kreymborg; Kristin Schneeweiss; Erich Michel; Sebastian Reuter; Jean-Christophe Renauld; Danielle Arnold-Schild; Hansjörg Schild; Roland Buhl; Burkhard Becher
Journal:  PLoS One       Date:  2011-07-18       Impact factor: 3.240

8.  Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus.

Authors:  Laurel A Monticelli; Gregory F Sonnenberg; Michael C Abt; Theresa Alenghat; Carly G K Ziegler; Travis A Doering; Jill M Angelosanto; Brian J Laidlaw; Cliff Y Yang; Taheri Sathaliyawala; Masaru Kubota; Damian Turner; Joshua M Diamond; Ananda W Goldrath; Donna L Farber; Ronald G Collman; E John Wherry; David Artis
Journal:  Nat Immunol       Date:  2011-11       Impact factor: 25.606

Review 9.  Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features.

Authors:  Eva Karamitopoulou
Journal:  Br J Cancer       Date:  2019-05-21       Impact factor: 7.640

10.  Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model.

Authors:  Stefanie Kirchberger; Daniel J Royston; Olivier Boulard; Emily Thornton; Fanny Franchini; Rose L Szabady; Oliver Harrison; Fiona Powrie
Journal:  J Exp Med       Date:  2013-05-06       Impact factor: 14.307

View more
  9 in total

1.  IL-22 Signaling in the Tumor Microenvironment.

Authors:  Runqiu Jiang; Beicheng Sun
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Dysregulation of ILC3s unleashes progression and immunotherapy resistance in colon cancer.

Authors:  Jeremy Goc; Mengze Lv; Nicholas J Bessman; Anne-Laure Flamar; Sheena Sahota; Hiroaki Suzuki; Fei Teng; Gregory G Putzel; Gerard Eberl; David R Withers; Janelle C Arthur; Manish A Shah; Gregory F Sonnenberg
Journal:  Cell       Date:  2021-08-17       Impact factor: 66.850

Review 3.  Innate lymphoid cells and cancer.

Authors:  Nicolas Jacquelot; Cyril Seillet; Eric Vivier; Gabrielle T Belz
Journal:  Nat Immunol       Date:  2022-02-28       Impact factor: 31.250

4.  IL-22 regulates inflammatory responses to agricultural dust-induced airway inflammation.

Authors:  Arzu Ulu; Stefanie Sveiven; Amanpreet Bilg; Jalene V Velazquez; Marissa Diaz; Maheswari Mukherjee; Ana G Yuil-Valdes; Santosh Kota; Abigail Burr; Aileen Najera; Tara M Nordgren
Journal:  Toxicol Appl Pharmacol       Date:  2022-05-05       Impact factor: 4.460

Review 5.  Innate Lymphoid Cells: Role in Immune Regulation and Cancer.

Authors:  Douglas C Chung; Nicolas Jacquelot; Maryam Ghaedi; Kathrin Warner; Pamela S Ohashi
Journal:  Cancers (Basel)       Date:  2022-04-21       Impact factor: 6.575

6.  Th22 Cells/IL-22 Serves as a Protumor Regulator to Drive Poor Prognosis through the JAK-STAT3/MAPK/AKT Signaling Pathway in Non-Small-Cell Lung Cancer.

Authors:  Yinan Yao; Guangdie Yang; Guohua Lu; Jiani Ye; Luyun Cui; Zhu Zeng; Junjun Chen; Jianying Zhou
Journal:  J Immunol Res       Date:  2022-05-28       Impact factor: 4.493

7.  EZH1/2 Inhibitors Favor ILC3 Development from Human HSPC-CD34+ Cells.

Authors:  Laura Damele; Adriana Amaro; Alberto Serio; Silvia Luchetti; Ulrich Pfeffer; Maria Cristina Mingari; Chiara Vitale
Journal:  Cancers (Basel)       Date:  2021-01-16       Impact factor: 6.639

Review 8.  Innate Lymphoid Cells: Emerging Players in Pancreatic Disease.

Authors:  Saimeng Shi; Longyun Ye; Kaizhou Jin; Zhiwen Xiao; Xianjun Yu; Weiding Wu
Journal:  Int J Mol Sci       Date:  2022-03-29       Impact factor: 5.923

9.  Human ILC3 Exert TRAIL-Mediated Cytotoxicity Towards Cancer Cells.

Authors:  Jana-Julia Siegler; Margareta P Correia; Tomáš Hofman; Isabel Prager; Emrullah Birgin; Nuh N Rahbari; Carsten Watzl; Ana Stojanovic; Adelheid Cerwenka
Journal:  Front Immunol       Date:  2022-03-01       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.